Could diabetes drugs protect kidneys after acute injury?
NCT ID NCT06528405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether SGLT2 inhibitors, drugs already used for diabetes and chronic kidney disease, can help people with acute kidney disease (AKD). AKD occurs between 7 and 90 days after a kidney injury and can lead to chronic kidney disease. The trial will give either the drug or a placebo to 264 adults with AKD, measuring changes in urine protein and kidney function. The goal is to see if these drugs can safely improve kidney outcomes and prevent long-term damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitors (dapagliflozin or empagliflozin)
What this could lead to
If successful, this could offer a new treatment to prevent acute kidney disease from turning into chronic kidney disease, improving long-term kidney health.
What could go wrong
This is an early phase 2 trial with only 264 participants, so results may not apply to everyone. The drugs may cause side effects like dehydration or infection, and the benefit is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Email: •••••@•••••